Bridget A. Ross Sells 3,750 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

LeMaitre Vascular Trading Down 0.3 %

NASDAQ:LMAT opened at $103.44 on Thursday. The firm has a fifty day simple moving average of $92.80 and a 200-day simple moving average of $86.35. LeMaitre Vascular, Inc. has a 12 month low of $51.70 and a 12 month high of $106.49. The company has a market capitalization of $2.33 billion, a P/E ratio of 56.52, a PEG ratio of 2.50 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period last year, the firm posted $0.33 EPS. Equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. LeMaitre Vascular’s payout ratio is 34.97%.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds have recently bought and sold shares of the business. NBC Securities Inc. grew its position in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 183 shares during the period. GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after acquiring an additional 199 shares in the last quarter. USA Financial Formulas purchased a new stake in shares of LeMaitre Vascular during the third quarter worth approximately $60,000. West Oak Capital LLC acquired a new position in LeMaitre Vascular in the 2nd quarter valued at $58,000. Finally, nVerses Capital LLC lifted its holdings in LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Wall Street Analyst Weigh In

LMAT has been the subject of a number of research analyst reports. JMP Securities raised their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Cantor Fitzgerald began coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target for the company. Lake Street Capital initiated coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective on the stock. Oppenheimer reissued an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, Barrington Research upped their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.